BioCardia
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
320 Soquel Way, Sunnyvale, California, 9...Phone Number
(650) 226-0120Website
www.biocardia.comRevenue
<$5 MillionStock Symbol
BCDAIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
2
1
1
About BioCardia
BioCardia is a clinical-stage regenerative medicine company focused on developing novel therapeutics for cardiovascular diseases with significant unmet medical needs. The company is advancing proprietary, comprehensive biotherapeutic solutions through its CardiAMP and CardiALLO therapy programs. Clinical results supporting both programs are compelling and build upon some of the most rigorous data to date in the field, utilizing intramyocardial delivery of marrow-derived cells.Explore more
BioCardia Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BioCardia your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if BioCardia had a recent Job posting/layoffs
Earning: See what the market has to say on BioCardia recently announced quarterly report
BioCardia, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when BioCardia launches new products
Check if BioCardia has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once BioCardia has new funding data
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at BioCardia
Check out if BioCardia is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined BioCardia as Masked Content
Find 2 more new buyers
Compare Similar Companies to BioCardia
Compare insights from companies similar to BioCardia, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
BioCardia is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
BioCardia is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about BioCardia.
BioCardia financials insights
Gather financial insights about BioCardia, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Debt
$4.4M
BioCardia Tech Stack
A closer look at the technologies used by BioCardia
Most Recent Scoops
Partnership
BioCardia is open to partnerships for its Cardialo cell therapy, highlighting its ability to manufacture clinical-grade cells at a competitive cost profile. The company is seeking partnerships for indications not currently being pursued.
Partnership, Healthcare Technology, Manufacturing Operations
Partnership
BioCardia has partnered with Zimmer Biomet for orthopedic applications of its cell processing platform in Japan. The company's Helix catheter system is the only new product to be introduced, and BioCardia views sponsors of other cardiac cell therapies as potential partners for its Helix biotherapeutic delivery system.
Partnership, Healthcare Technology
Partnership
BioCardia is engaged in partnering discussions for its Morph platform in the electrophysiology market, which is valued at over $10 billion per year. The company expects to announce details on a fusion imaging partnership that could benefit all of its product offerings and partnering efforts.
Partnership, Healthcare Technology
Project
BioCardia is preparing for FDA discussions regarding its Cardian therapy, which has FDA breakthrough designation, while simultaneously working on a de novo 510(k) submission for the Helix system. The Cardian Heart Failure II trial is actively enrolling patients at four centers, with a fifth center about to begin.
Medical Research, Clinical Operations, Healthcare Technology
Project
Healthcare Technology
BioCardia News & Media
BioCardia Announces Japan PMDA Record Of Advice Supports Regulatory Submission For Approval Of CardiAMP Cell Therapy For Ischemic Heart Failure
Submission Anticipated in Q4 2026 Submission Anticipated in Q4 2026BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency
– Positive CardiAMP CMI Trial open-label cohort results demonstrated opportunity for locally delivered cell therapy to enhance therapeutic options for patients with severely symptomatic refractory angina and validate continued clinical developmentBioCardia to Participate in a Fireside Chat at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
SUNNYVALE, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, will participate virtually in a fireside chat at A.G.P.'s Healthcare Company Showcase.BioCardia Inc (BCDA) Q1 2026 Earnings Call Highlights: Breakthroughs in Cardiac Therapy and ...
BioCardia Inc (BCDA) reports significant progress with FDA and Japanese regulatory advancements, alongside effective cost control measures despite financial challenges.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BioCardia
Sign Up For FreeTo access detailed company insights
BioCardia is a clinical-stage regenerative medicine company focused on developing novel therapeutics for cardiovascular diseases with significant unmet medical needs. The company is advancing proprietary, comprehensive biotherapeutic solutions through its CardiAMP and CardiALLO therapy programs. Clinical results supporting both programs are compell... Read More
